Navigation Links
Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent

AUSTIN, Texas, Aug. 1, 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Biomarkers for Peripheral Artery Disease." The patent claims cover the biomarker alpha1beta glycoprotein and biomarker combinations that include alpha1beta glycoprotein for the diagnosis of PAD.

"This will be our third patent for biomarkers that can be used for the diagnosis of PAD and represents a critical asset for Vermillion. Expanding our intellectual property portfolio helps protect the potential significant value of our PAD program as we progress our clinical studies," said Gail S. Page, CEO of Vermillion.

About Vermillion:

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.  Additional information about Vermillion can be found on the Web at

Forward-Looking Statement:

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q.  Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion Announces Joining Russell Microcap® Index
2. Vermillion Announces Notice of Allowance for Alzheimer Patent
3. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
4. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
5. Stephens Initiates Coverage on Vermillion
6. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
7. Vermillion Announces Issuance of European Patent
8. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
9. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
10. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
11. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announces Park NX10 SICM Module, an add-on scanning ion conductance microscopy module to ... of SICM to an AFM. , Park SICM benefits virtually all materials characterization ...
(Date:12/1/2015)... , December 1, 2015 Dr. Harry Lander , President ... serving as Chief Science Officer and recruits five ... Harry Lander , President of Regen, expands his role to ... recruits five distinguished scientists to join advisory team ... expands his role to include serving as ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced ... new closed system for isolating adipose-derived stem cells. The announcement starts a new phase ... tissue. SVF is a component of the lipoaspirate obtained from liposuction of excess adipose ...
(Date:11/30/2015)... Partnership includes an MPP ... the u niversity , s Solid Drug Nanoparticle ... cale - up through cost ... , where licensees based anywhere in the world will have the right to ... Africa , where licensees based anywhere in the world will have the ...
Breaking Biology Technology:
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... 29, 2015 Daon, a global leader in ... released a new version of its IdentityX Platform ... North America have already installed IdentityX v4.0 ... a FIDO UAF certified server component as ... activate FIDO features. These customers include some of the ...
Breaking Biology News(10 mins):